JP2022529502A - 抗ｃｄ３８抗体および製剤 - Google Patents

抗ｃｄ３８抗体および製剤 Download PDF

Info

Publication number
JP2022529502A
JP2022529502A JP2021562989A JP2021562989A JP2022529502A JP 2022529502 A JP2022529502 A JP 2022529502A JP 2021562989 A JP2021562989 A JP 2021562989A JP 2021562989 A JP2021562989 A JP 2021562989A JP 2022529502 A JP2022529502 A JP 2022529502A
Authority
JP
Japan
Prior art keywords
amino acid
antibody
seq
acid sequence
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021562989A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020219681A5 (fr
Inventor
ベアトリス・カメロン
マリエル・シロン・ブロンデル
ジャック・デュマ
アラン・フルニエ
ジョナサン・キングスベリー
センドリーヌ・レモワーヌ
ブライアン・マリー
ネイサン・オストバーグ
サンケット・パッケ
アンジェラ・ヴィロン－オッドス
ジシュアン・ジャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of JP2022529502A publication Critical patent/JP2022529502A/ja
Publication of JPWO2020219681A5 publication Critical patent/JPWO2020219681A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2021562989A 2019-04-23 2020-04-23 抗ｃｄ３８抗体および製剤 Pending JP2022529502A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962837518P 2019-04-23 2019-04-23
US62/837,518 2019-04-23
US201962859699P 2019-06-10 2019-06-10
US62/859,699 2019-06-10
EP20305146 2020-02-17
EP20305146.1 2020-02-17
EP20305145 2020-02-17
EP20305145.3 2020-02-17
PCT/US2020/029531 WO2020219681A1 (fr) 2019-04-23 2020-04-23 Formulations et anticorps anti-cd38

Publications (2)

Publication Number Publication Date
JP2022529502A true JP2022529502A (ja) 2022-06-22
JPWO2020219681A5 JPWO2020219681A5 (fr) 2023-05-01

Family

ID=70739160

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021562989A Pending JP2022529502A (ja) 2019-04-23 2020-04-23 抗ｃｄ３８抗体および製剤

Country Status (14)

Country Link
EP (1) EP3958898A1 (fr)
JP (1) JP2022529502A (fr)
KR (1) KR20220003562A (fr)
CN (1) CN114269375A (fr)
AU (1) AU2020261039A1 (fr)
BR (1) BR112021021060A2 (fr)
CA (1) CA3137365A1 (fr)
CO (1) CO2021015462A2 (fr)
IL (1) IL287477A (fr)
MA (1) MA55761A (fr)
MX (1) MX2021012967A (fr)
SG (1) SG11202111602YA (fr)
TW (1) TW202104269A (fr)
WO (1) WO2020219681A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024023843A1 (fr) * 2022-07-26 2024-02-01 Dr. Reddy’S Laboratories Limited Formulation pharmaceutique d'un anticorps thérapeutique et ses préparations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE443084T1 (de) 2004-07-10 2009-10-15 Fox Chase Cancer Ct Genetisch modifizierte, menschliche, natürliche killerzellenlinien:
EP1914242A1 (fr) * 2006-10-19 2008-04-23 Sanofi-Aventis Nouveau anticorps Anti-CD38 pour le traitement du cancer

Also Published As

Publication number Publication date
SG11202111602YA (en) 2021-11-29
CN114269375A (zh) 2022-04-01
KR20220003562A (ko) 2022-01-10
AU2020261039A1 (en) 2021-12-09
CO2021015462A2 (es) 2021-12-10
MX2021012967A (es) 2022-01-18
MA55761A (fr) 2022-03-02
TW202104269A (zh) 2021-02-01
EP3958898A1 (fr) 2022-03-02
BR112021021060A2 (pt) 2021-12-14
IL287477A (en) 2021-12-01
CA3137365A1 (fr) 2020-10-29
WO2020219681A1 (fr) 2020-10-29

Similar Documents

Publication Publication Date Title
US11427640B1 (en) CCR8 antibodies for therapeutic applications
CN111164100B (zh) 白介素-21突变蛋白和治疗方法
CN114341189A (zh) 全新il-15前药及其应用
CN111727197A (zh) 抗pd-1抗体和治疗方法
JP2020524506A (ja) 抗ｂｃｍａ重鎖のみ抗体
US11820824B2 (en) Antibodies to TIGIT
US20230203200A1 (en) Recruiting agent further binding an mhc molecule
TW202128131A (zh) 重組抗程式性細胞死亡受體1和抗分化抗原簇137雙特異性抗體製劑及其用途
BR112020004846A2 (pt) anticorpos de cadeia pesada que se ligam a ectoenzimas
JP2023530116A (ja) 抗ｓｉｒｐ－アルファ抗体
JP2022529502A (ja) 抗ｃｄ３８抗体および製剤
IL308257A (en) Antigen binding proteins that uniquely bind PRAME
EP3998081A1 (fr) Traitement du cancer hématologique avec une protéine à double spécificité pd-1/cd3
US20240182570A1 (en) Antibodies to tigit
CN118126157A (zh) 白介素-21突变蛋白和治疗方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230421

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230421

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240229

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240305